Slow Bull
The market, slowly. SATURDAY, 26 SEPTEMBER 2026

Acrivon Therapeutics, Inc.

ACRV Nasdaq SEC CIK 1781174
Follow Acrivon Therapeutics Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Net income −$18M +14.5% vs same quarter last year
EPS, diluted −$0.43 +21.8% vs same quarter last year
Operating cash flow −$14.9M +10.5% vs same quarter last year
Operating income −$18.7M +17.6% vs same quarter last year
Net income by quarter
−$22.4M
−$22.8M
−$19.7M
−$21M
−$18.2M
−$19M
−$19M
−$18M
Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income6 fiscal years
−$100M−$75M−$50M−$25M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$77.9M
FY24−$80.6M
FY23−$60.4M
FY22−$31.2M
FY21−$16.2M
FY20-
Free cash flowOperating cash flow minus capital expenditure
−$80M−$60M−$40M−$20M$0FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$65.3M
FY24−$68.4M
FY23−$43.9M
FY22−$32.3M
FY21−$14.2M
FY20-

News

No stories filed under Acrivon Therapeutics yet - coverage appears here as the news feed clusters it.